Fuller & Thaler Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.71M | Buy |
17,156
+1,917
| +13% | +$367K | 0.01% | 343 |
|
|
2026
Q1 | $2.79M | Buy |
15,239
+340
| +2% | +$62.6K | 0.01% | 356 |
|
|
2025
Q4 | $2.62M | Hold |
14,899
| – | – | 0.01% | 355 |
|
|
2025
Q3 | $2.09M | Hold |
14,899
| – | – | 0.01% | 363 |
|
|
2025
Q2 | $1.87M | Buy |
14,899
+6,231
| +72% | +$776K | 0.01% | 372 |
|
|
2025
Q1 | $1.19M | Buy |
8,668
+1,880
| +28% | +$269K | ﹤0.01% | 388 |
|
|
2024
Q4 | $1.04M | Buy |
6,788
+2,053
| +43% | +$346K | ﹤0.01% | 405 |
|
|
2024
Q3 | $918K | Buy |
4,735
+805
| +20% | +$168K | ﹤0.01% | 394 |
|
|
2024
Q2 | $911K | Buy |
3,930
+1,740
| +79% | +$378K | ﹤0.01% | 438 |
|
|
2024
Q1 | $472K | Sell |
2,190
-8
| -0.4% | -$1.87K | ﹤0.01% | 427 |
|
|
2023
Q4 | $569K | Buy |
2,198
+622
| +39% | +$153K | ﹤0.01% | 417 |
|
|
2023
Q3 | $405K | Buy |
1,576
+100
| +7% | +$26.7K | ﹤0.01% | 413 |
|
|
2023
Q2 | $420K | Buy |
1,476
+390
| +36% | +$116K | ﹤0.01% | 416 |
|
|
2023
Q1 | $302K | Hold |
1,086
| – | – | ﹤0.01% | 417 |
|
|
2022
Q4 | $301K | Sell |
1,086
-588
| -35% | -$166K | ﹤0.01% | 396 |
|
|
2022
Q3 | $447K | Sell |
1,674
-550
| -25% | -$117K | ﹤0.01% | 391 |
|
|
2022
Q2 | $454K | Sell |
2,224
-1,300
| -37% | -$266K | ﹤0.01% | 411 |
|
|
2022
Q1 | $742K | Buy |
3,524
+103
| +3% | +$22.4K | ﹤0.01% | 415 |
|
|
2021
Q4 | $821K | Sell |
3,421
-500
| -13% | -$129K | ﹤0.01% | 407 |
|
|
2021
Q3 | $1.11M | Sell |
3,921
-300
| -7% | -$98.3K | 0.01% | 390 |
|
|
2021
Q2 | $1.46M | Sell |
4,221
-700
| -14% | -$212K | 0.01% | 374 |
|
|
2021
Q1 | $1.38M | Sell |
4,921
-900
| -15% | -$243K | 0.01% | 357 |
|
|
2020
Q4 | $1.43M | Buy |
5,821
+11
| +0.2% | +$2.84K | 0.01% | 344 |
|
|
2020
Q3 | $1.65M | Hold |
5,810
| – | – | 0.02% | 313 |
|
|
2020
Q2 | $1.55M | Buy |
5,810
+2
| +0% | +$601 | 0.02% | 306 |
|
|
2020
Q1 | $1.84M | Sell |
5,808
-6,346
| -52% | -$1.93M | 0.03% | 273 |
|
|
2019
Q4 | $3.61M | Buy |
12,154
+2,105
| +21% | +$584K | 0.04% | 240 |
|
|
2019
Q3 | $2.34M | Hold |
10,049
| – | – | 0.03% | 268 |
|
|
2019
Q2 | $2.35M | Buy |
10,049
+1,819
| +22% | +$420K | 0.03% | 275 |
|
|
2019
Q1 | $1.95M | Sell |
8,230
-1,889
| -19% | -$595K | 0.02% | 285 |
|
|
2018
Q4 | $3.04M | Sell |
10,119
-2,710
| -21% | -$865K | 0.04% | 230 |
|
|
2018
Q3 | $4.53M | Sell |
12,829
-3,102
| -19% | -$1.07M | 0.05% | 224 |
|
|
2018
Q2 | $4.62M | Hold |
15,931
| – | – | 0.05% | 222 |
|
|
2018
Q1 | $4.36M | Sell |
15,931
-597
| -4% | -$185K | 0.05% | 216 |
|
|
2017
Q4 | $5.26M | Sell |
16,528
-3,072
| -16% | -$986K | 0.06% | 172 |
|
|
2017
Q3 | $6.14M | Buy |
19,600
+350
| +2% | +$104K | 0.08% | 150 |
|
|
2017
Q2 | $5.22M | Sell |
19,250
-1,400
| -7% | -$370K | 0.07% | 151 |
|
|
2017
Q1 | $5.65M | Buy |
20,650
+2,500
| +14% | +$707K | 0.08% | 148 |
|
|
2016
Q4 | $5.15M | Buy |
18,150
+3,500
| +24% | +$1.04M | 0.08% | 145 |
|
|
2016
Q3 | $4.59M | Buy |
14,650
+3,250
| +29% | +$963K | 0.08% | 149 |
|
|
2016
Q2 | $2.76M | Sell |
11,400
-3,000
| -21% | -$791K | 0.05% | 168 |
|
|
2016
Q1 | $3.75M | Buy |
+14,400
| New | +$3.8M | 0.07% | 145 |
|
|
2015
Q3 | – | Sell |
-1,500
| Closed | -$606K | – | 672 |
|
|
2015
Q2 | $606K | Sell |
1,500
-800
| -35% | -$321K | 0.02% | 295 |
|
|
2015
Q1 | $971K | Buy |
2,300
+1,900
| +475% | +$749K | 0.03% | 270 |
|
|
2014
Q4 | $136K | Sell |
400
-21,200
| -98% | -$6.86M | ﹤0.01% | 442 |
|
|
2014
Q3 | $7.14M | Buy |
21,600
+20,500
| +1,864% | +$6.76M | 0.31% | 89 |
|
|
2014
Q2 | $347K | Sell |
1,100
-2,600
| -70% | -$783K | 0.01% | 361 |
|
|
2014
Q1 | $1.13M | Buy |
3,700
+200
| +6% | +$63.5K | 0.05% | 250 |
|
|
2013
Q4 | $979K | Buy |
3,500
+600
| +21% | +$155K | 0.05% | 259 |
|
|
2013
Q3 | $698K | Sell |
2,900
-1,100
| -28% | -$246K | 0.04% | 273 |
|
|
2013
Q2 | $861K | Buy |
+4,000
| New | +$855K | 0.06% | 253 |
|
Other funds holding BIIB
Fuller & Thaler Asset Management's BIIB Position: Q2 2026 in Review
Fuller & Thaler Asset Management increased its Biogen (BIIB) stake by 13% in Q2 2026, buying an estimated $367K and bringing the position to 17,156 shares worth $3.71M. The position accounts for 0.01% of the portfolio, ranked #343.
Fuller & Thaler Asset Management first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $7.14M in Q3 2014. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Fuller & Thaler Asset Management held 17,156 shares of Biogen worth $3.71M as of Q2 2026.
- Fuller & Thaler Asset Management bought 1,917 Biogen shares in Q2 2026, an estimated $367K.
- Biogen made up 0.01% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #343 holding.
- Fuller & Thaler Asset Management first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
- Fuller & Thaler Asset Management's Biogen position peaked at $7.14M in Q3 2014.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.